Chemoprevention of colon and small intestinal tumorigenesis in APC Min/+ mice by licofelone, a novel dual 5-LOX/COX inhibitor: Potential implications for human colon cancer prevention

Cancer Prevention Research

Volumn 4, Issue 12, 2011, Pages 2015-2026

  Mohammed, Altaf ^a   Janakiram, Naveena B ^a   Li, Qian ^a   Choi, Chang In ^a   Zhang, Yuting ^a   Steele, Vernon E ^b   Rao, Chinthalapally V ^a  

^a UNIVERSITY OF OKLAHOMA COLLEGE OF MEDICINE   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APC PROTEIN; ARACHIDONATE 5 LIPOXYGENASE; ARACHIDONATE 5 LIPOXYGENASE ACTIVATING PROTEIN; CELECOXIB; CELL NUCLEUS ANTIGEN; CYCLOOXYGENASE 2; CYTOKINE; DEOXYURIDINE TRIPHOSPHATE PYROPHOSPHATASE; LEUKOTRIENE B4; LICOFELONE; PROSTAGLANDIN E SYNTHASE; PROSTAGLANDIN E SYNTHASE 2; TRIACYLGLYCEROL; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN EXPRESSION; APOPTOSIS; ARTICLE; CANCER PREVENTION; CARCINOGENESIS; CELL VOLUME; CHEMOPROPHYLAXIS; COLON CANCER; CONTROLLED STUDY; DIET; DIET THERAPY; ENZYME ACTIVITY; FEMALE; IMMUNOHISTOCHEMISTRY; MALE; MOUSE; NICK END LABELING; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; POLYP; PRIORITY JOURNAL; SMALL INTESTINE CANCER; TRIACYLGLYCEROL BLOOD LEVEL; TUMOR GROWTH; TUMOR VOLUME;

ADENOMATOUS POLYPOSIS COLI PROTEIN; ANIMALS; APOPTOSIS; ARACHIDONATE 5-LIPOXYGENASE; BLOTTING, WESTERN; CELL PROLIFERATION; COLONIC NEOPLASMS; CYCLOOXYGENASE 2; CYCLOOXYGENASE INHIBITORS; FEMALE; HUMANS; INTESTINAL NEOPLASMS; MALE; MICE; MICE, INBRED C57BL; PYRROLES; REAL-TIME POLYMERASE CHAIN REACTION; RNA, MESSENGER;

EID: 83055195235     PISSN: 19406207     EISSN: 19406215     Source Type: Journal    
DOI: 10.1158/1940-6207.CAPR-11-0233     Document Type: Article

References (46)

1. American Cancer Society 2011. Cancer facts and figures 2011 Atlanta, GA.
2. Reddy BS, Rao CV. Novel approaches for colon cancer prevention by cyclooxygenase-2 inhibitors. J Environ Pathol Toxicol Oncol 2002;21:155-64. (Pubitemid 34655036)
3. Reddy BS, Hirose Y, Lubet R, Steele V, Kellof G, Paulson S, et al. Chemoprevention of colon cancer by specific cyclooxygenase-2 inhibitor, celecoxib, administered during different stages of carcinogenesis. Cancer Res 2000;60:293-7. (Pubitemid 30070754)
4. Kawamori T, Rao CV, Seibert K, Reddy BS. Chemopreventive activity of celecoxib, a specific cyclooxygenase-2 inhibitor, against colon carcinogenesis. Cancer Res 1998;58:409-12. (Pubitemid 28087398)
5. Swamy MV, Herzog CR, Rao CV. Celecoxib inhibition of COX-2 in colon cancer cell lines increases the nuclear localization of functionally active p53. Cancer Res 2000;63:5239-42. (Pubitemid 37139836)
6. Rao CV, Wang CQ, Simi B, Rodriguez JG, Cooma I, El-Bayoumy K, et al. Chemoprevention of colon cancer by a glutathione conjugate of 1,4-phenylenebis(methylene) selenocyanate, a novel organoselenium compound with low toxicity. Cancer Res 2001;61:3647-52. (Pubitemid 32694975)
7. Bertagnolli MM, Eagle CJ, Zauber AG, Redston M, Breazna A, Kim KM, et al. Five-year efficacy and safety analysis of the Adenoma Prevention with Celecoxib Trial. Cancer Prev Res 2009;2:285-7
8. Rao CV, Swamy MV, Choi C, Janakiram NB, Patlolla JM, Steele VE. Chemoprevention of colon carcinogenesis by licofelone, a novel dual 5-LOX/COX inhibitor in F-344rats. AACR Meeting Abstracts, 2007;11.
9. Peters-Golden M, Henderson WR. Leukotrienes. N Engl J Med 2007;357:1841-54.
10. Capra V, Thompson MD, Sala A, Cole DE, Folco G, Rovati GE. Cysteinyl-leukotrienes and their receptors in asthma and other inflammatory diseases: critical update and emerging trends. Med Res Rev 2007;27:469-27.
11. 4 excretion: a biomarker of inflammatory bowel disease activity. Inflamm Bowel Dis 2008;14:769-74.
12. Avis IM, Jett M, Boyle T, Vos MD, Moody T, Treston AM, et al. Growth control of lung cancer by interruption of 5-lipoxygenase-mediated growth factor signaling. J Clin Invest 1996;97:806-13. (Pubitemid 26057100)
13. Sun Z, Sood S, Li N, Ramji D, Yang P,Newman RA, et al. Involvement of the 5-lipoxygenase/leukotriene A4 hydrolase pathway in 7,12-dimethylbenz[a] anthracene (DMBA)-induced oral carcinogenesis in hamster cheek pouch, and inhibition of carcinogenesis by its inhibitors. Carcinogenesis 2006;27:1902-8. (Pubitemid 44288671)
14. Soumaoro LT, Lida S, Uetake H, Ishiguro M, Takagi Y, Higuchi T, et al. Expression of 5-lipoxygenase in human colorectal cancer. World J Gastroenterol 2006;12:6355-60. (Pubitemid 44712419)
15. Ihara A, Wada K, Yoneda M, Fujisawa N, Takahashi H, Nakajima A. Blockade of leukotriene B4 signaling pathway induces apoptosis and suppresses cell proliferation in colon cancer. J Pharmacol Sci 2007;103:24-32. (Pubitemid 46175592)
16. Ye YN, Wu WKK, Shin VY, Bruce IC, Wong BCY, Cho CH. Dual inhibition of 5-LOX and COX-2 suppresses colon cancer formation promoted by cigarette smoke. Carcinogenesis 2005;26:827-34. (Pubitemid 41214346)
17. Shureiqi I, Lippman SM. Lipoxigenase modulation to reverse carcinogenesis. Cancer Res 2001;61:6307-12.
18. Steele VE, Holmes CA, Hawk ET, Kopelovich L, Lubet RA, Crowell JA, et al. Lipoxygenase inhibitors as potential cancer chemopreventives. Cancer Epidemiol Biomarkers Prev 1999;8:467-83. (Pubitemid 29230553)
19. Duffield-Lillico AJ, Boyle JO, Zhou XK, Ghosh A, Butala GS, Subbaramaiah K, et al. Levels of prostaglandin E metabolite and leukotriene E4 are increased in the urine of smokers: evidence that celecoxib shunts arachidonic acid into the 5-lipoxygenase pathway. Cancer Prev Res 2009;2:322-29.
20. Spanbroek R, Grabner R, Lotzer K, Hildner M, Urbach A, Ruhling K. Expanding expression of the 5-lipoxygenase pathway with the arterial wall during human atherogenesis. Proc Natl Acad Sci U S A 2003;100:1238-43. (Pubitemid 36183986)
21. Mehrabian M, Allayee H, Wong J, Shih W, Wang XP, Shaposhnik Z, et al. Identification of 5-lipoxygenase as a major gene contributing to atherosclerosis susceptibility in mice. Circ Res 2002;91:120-6. (Pubitemid 34827222)
22. Dwyer JH, Allayee H, Dwyer KM, Fan J, Wu H, Mar R, et al. Arachidonate 5-lipoxygenase promoter genotype, dietary arachidonic acid, and atherosclerosis. N Engl J Med 2004;350:29-37. (Pubitemid 38032181)
23. Helgadottir A, Manolescu A, Thorleifsson G, Gretarsdottir S, Jonsdottir H, Thorsteinsdottir U, et al. The gene encoding 5-lipoxygenase activating protein confers risk of myocardial infarction and stroke. Nat Genet 2004;36:233-9. (Pubitemid 38282747)
24. Funk CD. Leukotriene modifiers as potential therapeutics for cardiovascular disease. Nat Rev Drug Discov 2005;4:664-72. (Pubitemid 41149760)
25. Hakonarson H, Thorvaldsson S, Helgadottir A, Gudbjartsson D, Zink F, Andresdottir M, et al. Effects of a 5-lipoxygenase-activating protein inhibitor on biomarkers associated with risk of myocardial infarction. JAMA 2005;293:2245-56. (Pubitemid 40629191)
26. Leone S, Ottani A, Bertolini A. Dual acting anti-inflammatory drugs. Curr Top Med Chem 2007;7:265-75. (Pubitemid 46358660)
27. Cicero AF, Derosa G, Gaddi A. Combined lipoxygenase/cyclo-oxygenase inhibition in the elderly: the example of licofelone. Drugs Aging 2005;22:393-403.
28. Moreau M, Daminet S, Martel-Pelletier J, Fernandes J, Pelletier JP. Superiority of the gastroduodenal safety profile of licofelone over rofecoxib, a COX-2 selective inhibitor, in dogs. J Vet Pharmacol Ther 2005;28:81-86. (Pubitemid 40353798)
29. Bias P, Buchner A, Klesser B, Laufer S. The gastrointestinal tolerability of the LOX/COX inhibitor, licofelone, is similar to placebo and superior to naproxen therapy in healthy volunteers: results from a randomized, controlled trial. Am J Gastroenterol 2004;99:611-18. (Pubitemid 38607961)
30. Tavolari S, Bonafè M, Marini M, Ferreri C, Bartolini G, Brighenti E, et al. Licofelone, a dual COX/5-LOX inhibitor, induces apoptosis in HCA-7 colon cancer cells through the mitochondrial pathway independently from its ability to affect the arachidonic acid cascade. Carcinogenesis 2008;29:371-80. (Pubitemid 351359677)
31. Swamy MV, Patlolla JM, Steele VE, Kopelovich L, Reddy BS, Rao CV. Chemoprevention of familial adenomatous polyposis by low doses of atorvastatin and celecoxib given individually and in combination to APCMin mice. Cancer Res 2006;66:7370-7. (Pubitemid 44197721)
32. Jacoby RF, Marshall DJ, NewtonMA, Novakovic K, Tutsch K, Cole CE, et al. Chemoprevention of spontaneous intestinal adenomas in APC Min mouse model by the nonsteroidal anti-inflammatory drug piroxicam. Cancer Res 1996;56:710-4.
33. Rao CV, Reddy BS. NSAIDs and chemoprevention. Curr Cancer Drug Targets 2004;4:29-42. (Pubitemid 38332562)
34. Rao CV, Cooma I, Rodriguez JG, Simi B, El-Bayoumy K, Reddy BS. Chemoprevention of familial adenomatous polyposis development in the APC(min) mouse model by 1,4-phenylene bis(methylene)selenocyanate. Carcinogenesis 2000;21:617-21. (Pubitemid 30214015)
35. Orner GA, Dashwood WM, Blum CA, Díaz GD, Li Q, Dashwood RH. Suppression of tumorigenesis in the Apc(min) mouse: down-regulation of b-catenin signaling by a combination of tea plus sulindac. Carcinogenesis 2003;24:263-7. (Pubitemid 36267095)
36. Buchanan FG, Holla V, Katkuri S, Matta P, Dubios RN. Targetting cyclooxygenase-2 and the epidermal growth factor receptor for the prevention and treatment of intestinal cancer. Cancer Res 2007;67:9380-8. (Pubitemid 47535928)
37. Cianchi F, Cortesini C, Magnelli L, Fanti E, Papucci L, Schiavone N, et al. Inhibition of 5-lipoxygenase by MK886 augments the antitumor activity of celecoxib in human colon cancer cells. Mol Cancer Ther 2006;5:2716-26. (Pubitemid 44848998)
38. Yang VW, Shields JM, Hamilton SR, Spannhake EW, Hubbard WC, Hylind LM, et al. Size dependent increase in prostanoid levels in adenomas of patients with familial adenomatous polyposis. Cancer Res 1998;58:1750-3. (Pubitemid 28215104)
39. Sonoshita M, Takaku K, Sasaki N, Sugimoto Y, Ushikubi F, Narumiya S, et al. Acceleration of intestinal polyposis through prostaglandin receptor EP2 in Apc(D716) knockout mice. Nat Med 2001;7:1048-51. (Pubitemid 32937386)
40. Jupp J, Hillier K, Elliott DH, Fine DR, Bateman AC, Johnson PA, et al. Colonic expression of leukotriene-pathway enzymes in inflammatory bowel diseases. Inflamm Bowel Dis 2007;13:537-46. (Pubitemid 46799637)
41. Rao CV. Regulation of COX and LOX by curcumin. Adv Exp Med Biol 2007;595:213-26.
42. Reddy BS. Chemoprevention of colon cancer by select phytochemicals. Functional foods for disease prevention 1998;3:23-33.
43. Narayanan NK, Nargi D, Attur M, Abramson SB, Narayanan BA. Anticancer effects of licofelone (ML-3000) in prostate cancer cells. Anticancer Res 2007;27:2393-402. (Pubitemid 47228080)
44. Mutoh M, Takahashi M, Wakabayashi K. Roles of prostanoids in colon carcinogenesis and their potential targeting for cancer chemoprevention. Curr Pharm Des 2006;12:2375-82.
45. Kaminska J, Nowacki MP, Kowalska M, Rysinska A, Chwalinski M, Fuksiewicz M, et al. Clinical significance of serum cytokine measurements in untreated colorectal cancer patients: soluble tumor necrosis factor receptor Type I - An independent prognostic factor. Tumor Biol 2005;26:186-94. (Pubitemid 41379744)
46. Ueda T, Shimada E, Urakawa T. Serum levels of cytokines in patients with colorectal cancer: possible involvement of interleukin-6 and interleukin-8 in hematogenous metastasis. J Gastroenterol 1994;29:423-29. (Pubitemid 24262709)